Results 61 to 70 of about 546 (157)

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

open access: yesPharmaceuticals, 2023
Antibiotic resistance is a public health problem with increasingly alarming data being reported. Gram-positive bacteria are among the protagonists of severe nosocomial and community infections.
Davide Carcione   +13 more
doaj   +1 more source

Complicated and deep bacterial skin and soft tissue infections

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 3, Page 357-375, March 2025.
Summary Complicated erysipelas, cellulitis, and necrotizing soft tissue infections belong to the spectrum of bacterial infections affecting the skin and underlying soft tissues. Their frequency as well as risk of recurrence and complicated disease course pose a significant health burden.
Christine Prodinger   +7 more
wiley   +1 more source

Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 Staphylococcus and 1,068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019

open access: yesMicrobiology Spectrum, 2022
To evaluate the in vitro activities of eravacycline, tedizolid, nemonoxacin, norvancomycin, and ceftaroline against Staphylococcus and Enterococcus species isolates were collected as part of the China Antimicrobial Surveillance Network (CHINET) in 2019 ...
Li Ding   +9 more
doaj   +1 more source

Komplizierte und tiefe bakterielle Haut‐ und Weichteilinfektionen

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 3, Page 357-376, March 2025.
Zusammenfassung Komplizierte Erysipele, Phlegmone und nekrotisierende Weichteilinfektionen sind bakterielle Haut‐ und Weichteilinfektionen (BHWI), die aufgrund ihrer Häufigkeit, der Neigung zu Rezidiven und dem Auftreten komplizierter Verläufe ein bedeutendes Gesundheitsproblem darstellen.
Christine Prodinger   +7 more
wiley   +1 more source

In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria

open access: yes, 2017
Tedizolid is a new oxazolidinone with improved in vitro and intracellular potency against Mycobacterium tuberculosis , including multidrug-resistant strains, and some species of nontuberculous mycobacteria (
Richard J. Wallace   +1 more
core   +1 more source

Managing the Complex Intersection Between Substance Use Disorders and Infectious Diseases

open access: yes
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 3, March 2026.
Karissa Chow   +4 more
wiley   +1 more source

Acanthamoeba Infection in a Hematopoietic Cell Transplant Recipient: Challenges in Diagnosis, Management, and Source Identification

open access: yesTransplant Infectious Disease, Volume 27, Issue 1, January/February 2025.
Acanthamoeba infection in HCT recipients, represent multiple challenges. Early diagnosis, and effective treatment, remain the main barriers to survival. High index of suspicion, may help in identifying cases earlier. Given its ubiquiteness, source identification remains challenging.
Camellia T. Banerjee   +18 more
wiley   +1 more source

Linezolid‐Induced Glossitis and Papillitis in Orthopedic Patients With Postoperative Infection: A Case Report

open access: yesCase Reports in Infectious Diseases, Volume 2025, Issue 1, 2025.
Linezolid, an oxazolidinone antibiotic, is commonly used to treat Gram‐positive skin infections and has additional off‐label success in treating bone and soft tissue infections. Linezolid has been associated with adverse effects, particularly those that are hematologic and neurologic in nature.
Ryan J. Blake   +3 more
wiley   +1 more source

Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study

open access: yesAntibiotics, 2020
Objectives: Data on clinical and biological tolerance of tedizolid (TZD) prolonged therapy are lacking. Methods: We conducted a prospective multicentre study including patients with prosthetic joint infections (PJIs) who were treated for at least 6 weeks
Eric Senneville   +5 more
doaj   +1 more source

Characterization of the haematological profile of 21 days of tedizolid in healthy subjects.

open access: yes, 2016
Click on the Resource Link to access the article (may not be free).OBJECTIVES: Tedizolid is a novel oxazolidinone antibacterial. Oxazolidinones carry concerns for time-dependent myelosuppression. To further explore tedizolid's haematological tolerability,
Bidell, Monique R   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy